1/2
Export Ready

BORTLIEVA (BORTEZOMIB INJECTION IP 2 MG /VIAL

Sold by RADHAKRUSHNA MEDICALS · Distributor, Exporter, Wholesaler · Yavatmal, Maharashtra, India

Price
Price on request
In stock
Minimum order: 1 Piece

Export Snapshot

MOQ
1 Piece
Lead time
On request
Packaging
Standard export packaging
Shelf life / longevity
Manufacturer instructions apply
HSN Code
30049095
Origin
India
Port of dispatch
On request
Export markets served
United States flag US Philippines flag PH Smaller Territories of the UK flag XG United Kingdom flag GB Bangladesh flag BD +46 others
Values shown are for RADHAKRUSHNA MEDICALS.
Suitable for

Importers · Distributors · Wholesalers

Know your supplier

RADHAKRUSHNA MEDICALS is a Distributor, Exporter, Wholesaler based in Yavatmal Maharashtra India.

Yavatmal Dispatch on request Verified seller
RADHAKRUSHNA MEDICALS logo

Distributor, Exporter, Wholesaler · Yavatmal, Maharashtra, India

"Radhakrushna Medicals: Your Destination for Critical Care & Speciality Medicines. Surgical Suture Vaccines  "

Registered address: Yavatmal, India. Industry: Healthcare, Medical Supplies & Pharmaceuticals > Drugs & Pharmaceuticals.

Established
2022
Employees
1–10
GST
27AEMPT2491Q2ZF
IEC code
AEMPT2491Q
Export markets
United States flag US Philippines flag PH Smaller Territories of the UK flag XG United Kingdom flag GB Bangladesh flag BD +46 others
GlobalLinker Member Since
Feb 2026
Turnover
$50,000 - $250,000
Incorporation Type
On request
Product details

What are the specifications of this product?

Overview

Bortezomib Injection IP 2mgBrand Name BORTELIEVA 2MGComposition Bortezomib Injection IP 2mgManufacture By Allieva Pharma Private LimitedForm InjectionPacking VialCountry Of Origin India SCHEDULED  DRUG USED IN ONCOLOGY PRESCRIBED BY PHYSICIANS ONLYPrescription Required

Product Description

Description
BORTLIEVA 2 mg contains Bortezomib, a reversible proteasome inhibitor that inhibits the 26S proteasome. This leads to accumulation of misfolded proteins, disruption of cellular homeostasis, and apoptosis of malignant plasma cells. It is a key drug in multiple myeloma therapy.

Uses
Bortezomib is indicated for:

1. Multiple Myeloma
    – Newly diagnosed and relapsed/refractory

2. Mantle Cell Lymphoma (MCL)
    – Relapsed or refractory disease

Side Effects
Common side effects:

•  Peripheral neuropathy (dose-limiting)

•  Thrombocytopenia, anemia

•  Nausea, diarrhea, constipation

•  Fatigue

Other side effects:

•  Herpes zoster reactivation

•  Hypotension

Serious side effects:

•  Severe neuropathy

•  Heart failure (rare)

•  Pulmonary toxicity (rare)

Antiviral prophylaxis (e.g., acyclovir) is recommended.

Dosage
Dosage is based on body surface area (BSA).

Standard dose:

•  1.3 mg/m² per dose

Schedule:

•  IV or SC on Days 1, 4, 8, and 11 of a 21-day cycle

    2 mg vial is commonly used for single-dose preparation.

NOTE: This medicine should be taken only under a doctor’s supervision.

Description provided by RADHAKRUSHNA MEDICALS.

Specifications

Brand Name BORTLIEVA
Active Drug Bortezomib
Concentration 2 mg per vial
Formulation Type Injection IP
Dosage Form Injectable solution
Dosage Schedule Days 1,4,8,11 of 21-day cycle
Administration Route IV or SC
Therapeutic Area Oncology - Hematological malignancies
Indications Multiple Myeloma, Mantle Cell Lymphoma
Side Effects Peripheral neuropathy, thrombocytopenia, nausea
Packaging Size 1 vial per piece
Minimum Order Quantity (MOQ) 1 piece
Prescribed By Oncology specialists only
Storage Condition Manufacturer instructions apply
Schedule Scheduled drug
Manufacturer Allieva Pharma Private Limited
Country of Origin India

Use cases

Category Pharmaceuticals > Oncology Drugs > Proteasome Inhibitors
Primary application Wholesale, distribution, and international sourcing
Brand Not specified
Product type Product

Logistics & handling

Lead time On request
Packaging As per buyer requirement
Storage condition Manufacturer instructions apply
Origin India
Form As listed by supplier

Commercials (this seller)

Minimum order 1 Piece
Lead time On request
Payment terms As per negotiated commercial agreement.
Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing BORTLIEVA (BORTEZOMIB INJECTION IP 2 MG /VIAL. Answers compiled from verified sellers' commercial terms and platform data.

Q: What is the recommended dosing schedule for BORTLIEVA 2 mg Injection?
A: BORTLIEVA is typically administered at a dose of 1.3 mg/m² via IV or SC injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
Q: Is antiviral prophylaxis necessary when using BORTLIEVA?
A: Yes, antiviral prophylaxis such as acyclovir is recommended to prevent herpes zoster reactivation during treatment.
Q: Can BORTLIEVA be used for newly diagnosed multiple myeloma patients?
A: Yes, BORTLIEVA is indicated for both newly diagnosed and relapsed/refractory multiple myeloma cases.
Q: What are common side effects associated with BORTLIEVA?
A: Common side effects include peripheral neuropathy, thrombocytopenia, nausea, diarrhea, constipation, and fatigue.
Q: Is BORTLIEVA available as a single-dose vial?
A: Yes, BORTLIEVA comes as a single-dose 2 mg vial suitable for precise dose preparation.
Question not answered? Ask sellers directly — typical response within 4 hours.
BORTLIEVA (BORTEZOMIB INJECTION IP 2 MG /VIAL
BORTLIEVA (BORTEZOMIB INJECTION IP 2 MG /VIAL
Price on request · MOQ 1Piece